Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Features
AMS Features
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Off-label studies on ruxolitinib in dermatology: a review
By
Aesthetic Multispecialty Society
posted
Jun 09, 2020 03:25 AM
0
Recommend
.
0 comments
0 views
Related Content
Off-Label studies on anakinra in dermatology: a review
Aesthetic Multispecialty Society
Added Apr 22, 2020
Blog Entry
Off-label dermatologic uses of IL-17 inhibitors
Aesthetic Multispecialty Society
Added Mar 09, 2020
Blog Entry
On which evidence can we rely when prescribing off-label methotrexate in dermatological practice? – a systematic review with GRADE approach
Aesthetic Multispecialty Society
Added Aug 24, 2021
Blog Entry
FDA Warns on Use of Certain Surgical Mesh in Breasxt Reconstruction
Aesthetic Multispecialty Society
Added May 18, 2021
Blog Entry
Galderma Receives FDA Approval for New Sculptra Label, Offering More Options to Aesthetic Partners
Aesthetic Multispecialty Society
Added Jan 19, 2022
Blog Entry
Permalink
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic